- Home
- QNCX vs CCEL Comparison
QNCX vs CCEL Comparison
Compare QNCX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNCX
- CCEL
- Stock Information
- Founded
- QNCX 2012
- CCEL 1989
- Country
- QNCX United States
- CCEL United States
- Employees
- QNCX N/A
- CCEL N/A
- Industry
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- CCEL Managed Health Care
- Sector
- QNCX Health Care
- CCEL Health Care
- Exchange
- QNCX Nasdaq
- CCEL Nasdaq
- Market Cap
- QNCX 44.0M
- CCEL 51.9M
- IPO Year
- QNCX 2019
- CCEL 1997
- Fundamental
- Price
- QNCX $1.02
- CCEL $5.57
- Analyst Decision
- QNCX Strong Buy
- CCEL Strong Buy
- Analyst Count
- QNCX 5
- CCEL 1
- Target Price
- QNCX $8.00
- CCEL $8.50
- AVG Volume (30 Days)
- QNCX 138.1K
- CCEL 14.2K
- Earning Date
- QNCX 05-12-2025
- CCEL 04-21-2025
- Dividend Yield
- QNCX N/A
- CCEL 4.43%
- EPS Growth
- QNCX N/A
- CCEL N/A
- EPS
- QNCX N/A
- CCEL 0.05
- Revenue
- QNCX N/A
- CCEL $31,986,106.00
- Revenue This Year
- QNCX N/A
- CCEL $2.21
- Revenue Next Year
- QNCX N/A
- CCEL $0.98
- P/E Ratio
- QNCX N/A
- CCEL $114.05
- Revenue Growth
- QNCX N/A
- CCEL 2.05
- 52 Week Low
- QNCX $0.51
- CCEL $4.96
- 52 Week High
- QNCX $2.45
- CCEL $9.50
- Technical
- Relative Strength Index (RSI)
- QNCX 26.91
- CCEL 36.97
- Support Level
- QNCX $0.93
- CCEL $4.96
- Resistance Level
- QNCX $1.26
- CCEL $5.78
- Average True Range (ATR)
- QNCX 0.10
- CCEL 0.41
- MACD
- QNCX -0.03
- CCEL -0.05
- Stochastic Oscillator
- QNCX 18.03
- CCEL 36.09
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.